Ziresovir

Ziresovir
Clinical data
Trade names	Ziresovir
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-2H-1λ6,4-benzothiazepin-4-yl)-6-methylquinazolin-4-amine;
CAS Number	1422500-60-4;
PubChem CID	71262247;
ChemSpider	58810221;
UNII	XCF42D7AG4;
Chemical and physical data
Formula	C22H25N5O3S
Molar mass	439.53 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC2=C(C=C1)N=C(N=C2NCC3(COC3)N)N4CCS(=O)(=O)C5=CC=CC=C5C4;
	InChI InChI=1S/C22H25N5O3S/c1-15-6-7-18-17(10-15)20(24-12-22(23)13-30-14-22)26-21(25-18)27-8-9-31(28,29)19-5-3-2-4-16(19)11-27/h2-7,10H,8-9,11-14,23H2,1H3,(H,24,25,26); Key:GAAICKUTDBZCMT-UHFFFAOYSA-N;

Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials.^[1]^[2]^[3]